Trial Profile
A Phase II Preventative Trial of DFMO as a Single Agent in Patients With High Risk Neuroblastoma in Remission
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Eflornithine (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 18 Dec 2023 According to a Panbela Therapeutics media release, company announced that US WorldMeds (USWM), a Kentucky-based specialty pharmaceutical company to whom it divested certain assets in its eflornithine pediatric neuroblastoma program, received FDA approval of its New Drug Application for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma.
- 16 Jun 2022 According to a Panbela Therapeutics media release, Cancer Prevention Pharmaceuticals has been acquired by Panbela Therapeutics.
- 16 Mar 2020 Planned End Date changed from 1 Jun 2021 to 26 Apr 2021.